A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

August 1, 2026

Study Completion Date

December 31, 2026

Conditions

Breast Cancer

Interventions

DRUG

Disitamb Vedotin ,pyrotinib

Disitamb Vedotin combined with pyrotinib

Trial Locations (1)

RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

All Listed Sponsors

collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER